Source of Support: None, Conflict of Interest: None
The diagnosis of Duchenna Muscular Dystrophy (DMD) and Becker Muscular Dystorphy (BMD) is mainly based on clinical profile, serum CPK values, muscle biopsy and immunostaining for dystrophin. This was done in 100 unrelated patients using 19 exons including the promoter region in two sets of multiplex polymerase chain reaction (PCR). These primers amplify most of the exons in the deletion prone 'hot spot' regions allowing determinations of deletion end points. Intragenic deletions were detected in 74 patients indicating that the use of PCR- based assays will allow deletion detection help in prenatal diagnosis for most of the DMD/BMD patients. The frequency of deletions observed in the present study was 74%.